Anixa Biosciences Inc
AI Executive Summary
AI-powered analysis of 10-Q filing content
Anixa Biosciences shows concerning financial deterioration with zero revenue, accelerating cash burn, and diminishing runway. The company raised $1.6M through ATM offerings but continues burning $2.7M quarterly on R&D and G&A expenses, creating significant liquidity pressure.
Red Flags Detected (6)
Zero revenue generation despite ongoing operations
Net loss of $2.6M in Q1 with only $14.2M in liquid assets remaining
Quarterly burn rate of $2.7M provides less than 5 quarters of runway
3 more red flags detected
Key Takeaways
Pre-revenue biotech company with significant ongoing losses
R&D expenses of $1.1M suggest active drug development programs
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.